Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
188 hedge funds and large institutions have $286M invested in Esperion Therapeutics in 2025 Q3 according to their latest regulatory filings, with 48 funds opening new positions, 56 increasing their positions, 37 reducing their positions, and 20 closing their positions.
196% more capital invested
Capital invested by funds: $96.6M → $286M (+$189M)
140% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 20
51% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 37
15% more funds holding
Funds holding: 163 → 188 (+25)
4% more ownership
Funds ownership: 49.55% → 53.55% (+4%)
9% more call options, than puts
Call options by funds: $3.25M | Put options by funds: $2.99M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
+$6.36M |
| 2 |
Morgan Stanley
New York
|
+$5.8M |
| 3 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$5.8M |
| 4 |
RA
Royce & Associates
New York
|
+$4.44M |
| 5 |
IHAM
Integral Health Asset Management
New York
|
+$2.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$6.34M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$5.4M |
| 3 |
ICM
Indaba Capital Management
San Francisco,
California
|
-$2.95M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$2.17M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.54M |
ESPR Hedge Fund Activity: Q3 2025 in Review
188 of the 7,638 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q3 2025, worth a combined $286M — up 196% from $96.6M a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new ESPR positions and 20 closed out — a net gain of 28 holders — while 56 added to existing stakes and 37 trimmed.
The largest buyer was Nuveen, adding an estimated $6.36M. The largest seller was Wasatch Advisors, cutting an estimated $6.34M.
- 188 institutional investors held Esperion Therapeutics (ESPR) as of Q3 2025, up from 163 in Q2 2025.
- Funds reported $286M of Esperion Therapeutics stock for Q3 2025, up 196% quarter-over-quarter.
- 48 funds opened new Esperion Therapeutics positions in Q3 2025 and 20 closed out, a net change of +28 holders.
- The largest Esperion Therapeutics buyer in Q3 2025 was Nuveen, an estimated $6.36M added.
- The largest Esperion Therapeutics seller in Q3 2025 was Wasatch Advisors, an estimated $6.34M sold.
Based on aggregated 13F filings for Q3 2025.